In April xxxx, United States Rifaximin prices fell marginally following the modest price increase of March. This was the result of balanced inventories on both sides, picky buying on Rifaximin by downstream formulators of pharmaceuticals, and broader movements in international trade policies that have impacted near-term supply-demand movements.
The month opened on the shoulders of defensive sentiment among the market players, in the aftermath of the March restocking during which prices had increased due to expected disruptions to international trade flows. Inventories having been restored to adequate levels and there being no near-term supply shocks early in April, the buyers held back, deferring from over-procuring and letting Rifaximin prices dip modestly. Rifaximin prices attained their levels at USD xxxxxx/MT CFR Los Angeles towards the end of April.
Overshadowing the market space was the application of a xxxx tariff on April xx, xxxx,...
